Last reviewed · How we verify
NCT03191643
PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer
trial in Differentiated Thyroid Cancer in 16 participants. Completed in 31 January 2016.
31 January 2016
Quick facts
| Lead sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 16 |
| Start date | 1 October 2011 |
| Primary completion | 31 January 2016 |
| Estimated completion | 31 January 2016 |
Conditions studied
- Differentiated Thyroid Cancer — all drugs for Differentiated Thyroid Cancer →
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →
Who can join
18 and older, any sex, with Differentiated Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Description of the role of a post-operative external beam radiotherapy in patients with differentiated thyroid cancer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Hypoxia in Solid Tumors: How Low Oxygenation Impacts the "Six Rs" of Radiotherapy.
Rakotomalala A, Escande A, Furlan A, Meignan S, et al · · 2021 · cited 68× · PMID 34539584 · DOI 10.3389/fendo.2021.742215 -
<sup>18</sup>F-FDG Pet-Guided External Beam Radiotherapy in Iodine-Refractory Differentiated Thyroid Cancer: A Pilot Study.
Farina E, Monari F, Castellucci P, Romani F, et al · · 2017 · cited 1× · PMID 29201490 · DOI 10.1155/2017/9807543
Verify or expand the search:
- PubMed search for NCT03191643
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Differentiated Thyroid Cancer
Currently open trials in the same condition.
- NCT07436455 — F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer · NA · recruiting
- NCT06458036 — Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) · Phase 2 · recruiting
- NCT05783323 — Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer · Phase 2 · recruiting
- NCT05989425 — Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer · Phase 2 · recruiting
- NCT05599139 — Iodine Uptake After a Low Iodine Diet · NA · recruiting
Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials
Trials by the same sponsor.
- NCT06718049 — Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juveni · not yet recruiting
- NCT07490392 — Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantati · not yet recruiting
- NCT07483853 — Reliability and Validation of the WB-MRI Radiological Score in CRMO · recruiting
- NCT07479121 — These Studies Assess Surgeons' Physical and Ergonomic Workloads. Study 1 Compares Laparoscopic vs. Hugo RAS Robotic Appr · NA · not yet recruiting
- NCT07471009 — Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Sq · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03191643 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Last refreshed: 19 June 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03191643.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing